157 related articles for article (PubMed ID: 16601442)
1. New approaches in hormone refractory prostate cancer.
Sonpavde G; Hutson TE
Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
[TBL] [Abstract][Full Text] [Related]
2. Hormone refractory prostate cancer: Management and advances.
Sonpavde G; Hutson TE; Berry WR
Cancer Treat Rev; 2006 Apr; 32(2):90-100. PubMed ID: 16458434
[TBL] [Abstract][Full Text] [Related]
3. [New targeted therapies in hormone-refractory prostate cancer].
Oudard S; Banu E; Scotte F; Beuzeboc P; Guyader C; Medioni J
Bull Cancer; 2007 Jul; 94(7 Suppl):F62-8. PubMed ID: 17845995
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of hormone refractory prostate cancer: new standards, new trends].
Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D
BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic approaches to advanced prostate cancer.
Armstrong AJ; Carducci MA
Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
[TBL] [Abstract][Full Text] [Related]
8. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
9. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
Bhandari MS; Petrylak DP; Hussain M
Eur J Cancer; 2005 Apr; 41(6):941-53. PubMed ID: 15808960
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
Gulley J; Dahut WL
Urology; 2003 Dec; 62 Suppl 1():147-54. PubMed ID: 14747053
[TBL] [Abstract][Full Text] [Related]
12. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.
Canales BK; Li Y; Thompson MG; Gleason JM; Chen Z; Malaeb B; Corey DR; Herbert BS; Shay JW; Koeneman KS
Urol Oncol; 2006; 24(2):141-51. PubMed ID: 16520278
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
14. Castration-refractory prostate cancer: New drugs in the pipeline.
Schrijvers D; Van Erps P; Cortvriend J
Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel for the treatment of prostate cancer.
Gilbert DC; Parker C
Future Oncol; 2005 Jun; 1(3):307-14. PubMed ID: 16556003
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
Fischel JL; Ciccolini J; Formento P; Ferrero JM; Milano G
Anticancer Drugs; 2006 Aug; 17(7):807-13. PubMed ID: 16926630
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.
Olbert PJ; Hegele A; Kraeuter P; Heidenreich A; Hofmann R; Schrader AJ
Anticancer Drugs; 2006 Sep; 17(8):993-6. PubMed ID: 16940810
[TBL] [Abstract][Full Text] [Related]
19. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
20. Management of prostate cancer. Part 3: metastatic disease.
Shah J; Khaksar SJ; Sooriakumaran P
Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
